Selected article for: "cc NC ND International license and pulmonary disease"

Author: Jun Fei; Lin Fu; Ying Li; Hui-Xian Xiang; Ying Xiang; Meng-Die Li; Fang-Fang Liu; De-xiang Xu; Hui Zhao
Title: Reduction of lymphocyte at early stage elevates severity and death risk of COVID-19 patients: a hospital-based case-cohort study
  • Document date: 2020_4_6
  • ID: 8q1veo3q_17
    Snippet: Lymphocyte percentage in males were obviously lower than those in females (16.1% (Table 3) . Interestingly, we found that lymphocyte percentage in patients with cardiac disease and pulmonary disease were prominently lower than those in patients without cardiac disease and pulmonary disease (12.0% vs 20.6%, P=0.028; 10.6% vs 20.1%, P=0.045 ). Multivariable logistic regression was used to analyze risk factors of lymphocyte reduction in 192 pati.....
    Document: Lymphocyte percentage in males were obviously lower than those in females (16.1% (Table 3) . Interestingly, we found that lymphocyte percentage in patients with cardiac disease and pulmonary disease were prominently lower than those in patients without cardiac disease and pulmonary disease (12.0% vs 20.6%, P=0.028; 10.6% vs 20.1%, P=0.045 ). Multivariable logistic regression was used to analyze risk factors of lymphocyte reduction in 192 patients with COVID-19. As shown in Table 4 , the OR of lymphocyte reduction in patients from 60 to 69 years old was 0.290 (95% Cl: 0.096, 0.874; P=0.028), the OR . CC-BY-NC-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

    Search related documents:
    Co phrase search for related documents
    • cardiac disease and International license: 1, 2
    • cardiac disease and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • cardiac disease and lymphocyte reduction: 1
    • cardiac disease and multivariable logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • cardiac disease and pulmonary disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • cardiac disease and pulmonary disease cardiac disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • cardiac disease and risk factor: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • cc NC ND International license and International license: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • cc NC ND International license and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • cc NC ND International license and lymphocyte percentage: 1
    • cc NC ND International license and lymphocyte reduction: 1, 2, 3, 4, 5
    • cc NC ND International license and multivariable logistic regression: 1, 2, 3
    • cc NC ND International license and pulmonary disease: 1, 2, 3, 4, 5, 6, 7
    • cc NC ND International license and risk factor: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • International license and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
    • International license and lymphocyte percentage: 1
    • International license and lymphocyte reduction: 1, 2, 3, 4, 5
    • International license and multivariable logistic regression: 1, 2, 3
    • International license and pulmonary disease: 1, 2, 3, 4, 5, 6, 7